SQSTM1 (sequestosome 1; also known as p62) encodes a multidomain scaffolding protein involved in various key cellular processes, including the removal of damaged mitochondria by its function as a selective autophagy receptor. Heterozygous variants in SQSTM1 have been associated with Paget disease of the bone and might contribute to neurodegeneration in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Using exome sequencing, we identified three different biallelic loss-of-function variants in SQSTM1 in nine affected individuals from four families with a childhood- or adolescence-onset neurodegenerative disorder characterized by gait abnormalities, ataxia, dysarthria, dystonia, vertical gaze palsy, and cognitive decline....
Genetics has a major role in early-onset dementia, but the correspondence between genotype and pheno...
Summary: In response to lysosomal damage, cells engage several quality-control mechanisms, including...
OBJECTIVE: To characterize clinically and molecularly an early-onset, variably progressive neurodege...
SQSTM1 (sequestosome 1; also known as p62) encodes a multidomain scaffolding protein involved in var...
Objective: There is increasing evidence that common genetic risk factors underlie frontotemporal lob...
Abstract Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterize...
Several studies reported amyotrophic lateral sclerosis (ALS)-linked mutations in TBK1, OPTN, VCP, UB...
Objective To characterize clinically and molecularly an early-onset, variably progressive neurodegen...
Amyotrophic lateral sclerosis and associated frontotemporal lobe dementia (ALS- FTLD) is a complex, ...
The multidomain scaffold protein p62 (also called sequestosome-1) is involved in autophagy, antimicr...
Objective: To characterize clinically and molecularly an early-onset, variably progressive neurodege...
Frontotemporal dementia includes a large spectrum of neurodegenerative disorders. SQSTM1, coding for...
Mutations in SQSTM1, encoding for the protein SQSTM1/p62, have been recently reported in 1-3.5% of p...
Growing evidence implicates impairment of autophagy as a candidate pathogenic mechanism in the spect...
Growing evidence implicates impairment of autophagy as a candidate pathogenic mechanism in the spect...
Genetics has a major role in early-onset dementia, but the correspondence between genotype and pheno...
Summary: In response to lysosomal damage, cells engage several quality-control mechanisms, including...
OBJECTIVE: To characterize clinically and molecularly an early-onset, variably progressive neurodege...
SQSTM1 (sequestosome 1; also known as p62) encodes a multidomain scaffolding protein involved in var...
Objective: There is increasing evidence that common genetic risk factors underlie frontotemporal lob...
Abstract Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterize...
Several studies reported amyotrophic lateral sclerosis (ALS)-linked mutations in TBK1, OPTN, VCP, UB...
Objective To characterize clinically and molecularly an early-onset, variably progressive neurodegen...
Amyotrophic lateral sclerosis and associated frontotemporal lobe dementia (ALS- FTLD) is a complex, ...
The multidomain scaffold protein p62 (also called sequestosome-1) is involved in autophagy, antimicr...
Objective: To characterize clinically and molecularly an early-onset, variably progressive neurodege...
Frontotemporal dementia includes a large spectrum of neurodegenerative disorders. SQSTM1, coding for...
Mutations in SQSTM1, encoding for the protein SQSTM1/p62, have been recently reported in 1-3.5% of p...
Growing evidence implicates impairment of autophagy as a candidate pathogenic mechanism in the spect...
Growing evidence implicates impairment of autophagy as a candidate pathogenic mechanism in the spect...
Genetics has a major role in early-onset dementia, but the correspondence between genotype and pheno...
Summary: In response to lysosomal damage, cells engage several quality-control mechanisms, including...
OBJECTIVE: To characterize clinically and molecularly an early-onset, variably progressive neurodege...